Abstract:Liver cirrhosis is the pathologic end stage of chronic liver disease. Increasing evidence suggests that gut flora is implicated in the pathogenesis of liver cirrhosis complications. The aim of this study was to characterize the fecal microbial communities in patients with liver cirrhosis in comparison with healthy individuals. We recruited 36 patients with liver cirrhosis and 24 healthy controls. The fecal microbial community was analyzed by way of 454 pyrosequencing of the 16S ribosomal RNA V3 region followed by real-time quantitative polymerase chain reaction. Community-wide changes of fecal microbiota in liver cirrhosis were observed compared with healthy controls. The proportion of phylum Bacteroidetes was significantly reduced (P = 0.008), whereas Proteobacteria and Fusobacteria were highly enriched in the cirrhosis group (P = 0.001 and 0.002, respectively). Enterobacteriaceae (P = 0.001), Veillonellaceae (P = 0.046), and Streptococcaceae (P = 0.001) were prevalent in patients with cirrhosis at the family level. A positive correlation was observed between Child-Turcotte-Pugh (CTP) score and Streptococcaceae (R = 0.386, P = 0.02). Lachnospiraceae decreased significantly in patients with cirrhosis (P = 0.004) and correlated negatively with CTP score (R = -0.49, P = 0.002). Using partial least square discriminate analysis, we identified 149 operational taxonomic units (OTUs) as key phylotypes that responded to cirrhosis, most of which were Lachnospiraceae (65 OTUs), Streptococcaceae (23 OTUs), and Veillonellaceae (21 OTUs). Conclusion: Fecal microbial communities are distinct in patients with cirrhosis compared with healthy individuals. The prevalence of potentially pathogenic bacteria, such as Enterobacteriaceae and Streptococcaceae, with the reduction of beneficial populations such as Lachnospiraceae in patients with cirrhosis may affect prognosis. (HEPATOLOGY 2011;54:562-572)

The regulatory role of bile acid microbiota in the progression of liver cirrhosis

Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver–Gut Axis

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease

Critical Roles of Bile Acids in Regulating Intestinal Mucosal Immune Responses

Modulation of bile acid profile by gut microbiota in chronic hepatitis B

Modulation of the fecal bile acid profile by gut microbiota in cirrhosis

Bile acid-mediated signaling in cholestatic liver diseases

Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology

The role of enterohepatic circulation of bile acids and intestinal microbiota in the pathogenesis and treatment of cholestatic liver disease

The molecular insights of bile acids homeostasis in host diseases

Bile acid metabolism and signalling in liver disease

Role of bile acids in liver diseases mediated by the gut microbiome

Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases

Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma

Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions

New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease

Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease

Characterization of Fecal Microbial Communities in Patients with Liver Cirrhosis.

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease

Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease

The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease